Heron Neutron Medical Corp

The company maintains a strong liquidity position, with cash and equivalents amounting to TWD 500 million, representing 4.3% of total assets. The price-to-book ratio of 4.57 and a current ratio of 162.91 indicate a highly liquid balance sheet with minimal leverage, as the debt-to-equity ratio is effectively zero. However, the company is experiencing negative operating cash flow of TWD -484.4 million and free cash flow of TWD -472.1 million, which suggests ongoing operational challenges. Profitability metrics are negative, with a return on equity of -4.19% and a return on assets of -4.16%. The company reported a net loss of TWD -481.7 million for the period, with operating income at TWD -534.3 million and gross profit at TWD -25.8 million. These figures are significantly below the industry median for profitability metrics, indicating underperformance relative to peers. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of segment or geographic diversification increases exposure to sector-specific risks and limits visibility into potential growth drivers. The company's revenue outlook is uncertain, with no disclosed growth trajectory in the provided data. Analysts have assigned a mean price target of TWD 1,175, significantly higher than the current market price of TWD 333, but the absence of disclosed revenue growth or margin improvement plans raises questions about the achievability of these targets. Risk factors include the company's negative operating cash flow and free cash flow, which could pressure liquidity if sustained. The risk assessment indicates low dilution risk, with no immediate filing-based dilution flags detected. However, the absence of disclosed capital raising plans or dilution sources does not preclude future dilution if operational performance does not improve. Recent events include the publication of the latest financial data, which shows continued losses and negative cash flows. No recent filings or transcripts were provided to indicate strategic shifts or operational improvements.